Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.75 |
| ▸ | TNF | P01375 | 4/20 | 0.75 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.75 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.75 |
| ▸ | IL1B | P01584 | 3/20 | 0.75 |
| ▸ | BRD4 | O60885 | 1/20 | 0.75 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25031818 | 1.00 | CRBN (0.77) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL23565076 | 0.91 | CRBN (0.72) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL29767481 | 0.89 | CRBN (0.61) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL31727916 | 0.87 | CRBN (1.00) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL29453150 | 0.87 | CRBN (1.00) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL1097880 | 0.87 | CRBN (1.00) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL20442491 | 0.87 | CRBN (1.00) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL868592 | 0.86 | CRBN (0.75) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL21462288 | 0.86 | CRBN (0.75) | CRBNIKZF3TNFIKZF1DDB1 | |
| SCHEMBL21602701 | 0.86 | CRBN (0.75) | CRBNIKZF3TNFIKZF1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4676929-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECH LTD (GB) | 2025-05-15 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| EP-4479400-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | Cancer Research Technology Limited (GB) | 2024-12-25 | — | — | EP | disclosed |
| CN-119053604-A | Heterocyclic compounds for the treatment of ERK5 mediated diseases | 癌症研究技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | disclosed |
| US-20200277305-A1 | BET Bromodomain Protein Degraders with Cleavable Linkers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| WO-2020142227-A1 | ESTROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
| US-20190263827-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263827-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3512853-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | The Regents of The University of Michigan (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2019055444-A1 | BET BROMODOMAIN PROTEIN DEGRADERS WITH CLEAVABLE LINKERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018052949-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018052949-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277305-A1 | BET Bromodomain Protein Degraders with Cleavable Linkers | BRD4, BET1, BRWD1 | CRBN 142/4885IKZF3 453/4885TNF 4467/4885 |
| US-20190263827-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BRD1, BET1 | CRBN 114/4885IKZF3 206/4885TNF 4719/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | CRBN 833/4885IKZF3 799/4885TNF 976/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | CRBN 39/4885IKZF3 989/4885TNF 2317/4885 |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | MAP3K5, MAPK1, MAP3K20 | CRBN 2451/4885IKZF3 3510/4885TNF 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.